A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease

<div>Forest plots of the standardized mean difference in Unified Parkinson’s Disease Rating Scale II (UPDRS II (a)) and III (UPDRS III (b)) following the administration of pramipexole. Pramipexole improved both UPDRS II and UPDRS III scores. Significant heterogeneity was seen in the included studies.</div>

Parkinson’s Disease

fig4

Figure 4

Figure 4: A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease 

Figure 4 | A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease 